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Cerebral cavernous malformations (CMs) are dynamic lesions characterized by continuous
size changes and repeated bleeding. When involving cortical tissue, CMs pose a signiﬁ-
cant risk for the development of drug-resistant epilepsy, which is thought to be result of an
altered neuronal network caused by the lesion itself and its blood degradation products.
Preoperative evaluation should comprise a complete seizure history, neurological exam-
ination, epilepsy-oriented MRI, EEG, video-EEG, completed with SPECT, PET, functional
MRI, and/or invasive monitoring as needed. Radiosurgery shows variable rates of seizure
freedom and a high incidence of complications, thus microsurgical resection remains the
optimal treatment for CMs presenting with drug-resistant epilepsy. Two thirds of patients
reach Engel I class at 3-year follow-up, regardless of lobar location. Those with secon-
darily generalized seizures, a higher seizure frequency, and generalized abnormalities on
preoperative or postoperative EEG, show poorer outcomes, while factors such as gender,
duration of epilepsy, lesion size, age, bleeding at the timeof surgery, do not correlate consis-
tently with seizure outcome. Electrocorticography and a meticulous removal of all cortical
hemosiderin – beyond pure lesionectomy – reduce the risk of symptomatic recurrences.
Keywords: epilepsy surgery, cavernous malformation, drug-resistant epilepsy, electrocorticography, partial onset
epilepsy
INTRODUCTION
Cerebral cavernous malformations (CMs), also known as cav-
ernous angiomas, cavernomas, or cavernous hemangiomas, were
ﬁrst described in the central nervous system by Virchow in
1863 (Iza-Vallejo et al., 2005) and characterized microscopi-
cally by Mccormick (1966). These mulberry-like lesion consist
of intertwined clusters of thin-walled vascular sinusoids lined by
a thin endothelium lacking smooth muscle, elastin, and inter-
vening parenchyma, surrounded by hemosiderin deposits and
gliosis (Raychaudhuri et al., 2005). CMs account for about 10%
of all symptomatic vascular malformations, being the most fre-
quent angiographically occult intracranial vascularmalformations
(Gomori et al., 1986), with an estimated frequency of 0.4–0.9%
(Otten et al., 1989; Brown et al., 2005), and an annual bleed-
ing rate laying somewhere between 0.7 and 1.4%/lesion/year, or
0.25–3.1%/person/year of exposure (Kim et al., 1997; Stefan and
Hammen, 2004; Ferroli et al., 2006).
Their occurrence can be sporadic, or as an autosomal dominant
condition with variable expression and incomplete penetrance.
The ﬁrst recognized gene association (CCM1), was mapped in the
long arm of chromosome 7 (7q11 to tq12), upon studying the
familial form of CM in a Hispanic family (Dubovsky et al., 1995).
Three genes implied in the pathogenesis have been identiﬁed, all
of them expressed in neurons rather than in blood vessels, sug-
gesting an impaired signaling between these structures (Revencu
and Vikkula, 2006).
It is well recognized the changing nature of CMs. This
dynamism is determined by both extrinsic – hemorrhage,
calciﬁcations, thrombosis, and intrinsic factors – pseudotumoral
growth of the cavernous matrix – that result in growing or shrink-
ing of established malformation; and by pathologic angiogenic
factors in de novo appearing lesions (Houtteville, 1997).
CMS AND EPILEPSY
Clinical manifestations, when present, are variable and include
headache, seizures, hemorrhage, and sudden onset focal neuro-
logical deﬁcits (FND; Raychaudhuri et al., 2005). The latter are
the most common presentation of brainstem lesions, whereas
seizures are the most frequent manifestation of supratentorial
lesions (Awad and Jabbour, 2006; Van Gompel et al., 2010).
Epileptic seizures linked to CMs are often drug-resistant
(Robinson et al., 1991; Kim et al., 1997). Cortical involvement
is the most relevant risk factor for epilepsy. A greater diameter,
the absence of edema, and localization in the left hemisphere are
also associated with the occurrence of epilepsy. Mesiotemporal
archicortical CMs pose a signiﬁcantly higher risk for the devel-
opment of epilepsy than neocortical lesions, a group that shows
no differences regarding lobar location (Yeon et al., 2009; Men-
zler et al., 2010). Patients with peri-limbic or anterior temporal
lesionsmay show signs of dual pathology, consistent inmacroscop-
ically – hippocampal sclerosis –microscopically, or only functional
abnormalities within themesial temporal lobe (Cendes et al., 1995;
Stefan and Hammen, 2004).
The mass effect does not completely account for CMs’ high
epileptogenicity, as the clinicianmay appreciate when dealing with
larger lesions, namely other kinds of AVMs – in the absence of
www.frontiersin.org January 2012 | Volume 2 | Article 86 | 1
Alonso-Vanegas et al. Epilepsy surgery for cavernous malformations
prior hemorrhage or FND – and gliomas, which are less likely to
present with seizures (Awad et al., 1991; Josephson et al., 2011).
This feature, referred to as secondary epileptogenesis (Morrell,
1985), has been studied in CMs. Williamson et al. (2003) per-
formed intracellular recordings from neurons adjacent to gliomas
and cavernomas, ﬁnding that neurons adjacent to CMs were more
likely to show large complex spontaneous synaptic events than
neurons adjacent to tumors. These neurons also showedmore pro-
nounced responses to synaptic stimulation, e.g., multiple action
potentials riding on prolonged excitatory postsynaptic potentials
were evoked in the majority of these cells, as opposed to those
belonging to the tumor group (Williamson et al., 2003).
Intralesional bleeding is another factor to consider. This event
may partially destroy the CM, leaving residual cysts, and calciﬁ-
cations (Pozzati et al., 1989). It is thought that the breakdown of
blood products results in gradual deposition of hemosiderin and
hemin in the cerebral tissue surrounding the malformation (Kim
et al., 1997); ultimately leading to biochemical abnormalities that
becomemore prevalent and signiﬁcant as the duration of epilepsy
continues. The lattermight explainwhy a longer history of epilepsy
is a predictive of poorer results following pure lesionectomy, i.e.,
restricted surgical removal of the CM, respecting the hemosiderin-
stained gliotic perilesional tissue (Ferroli et al., 2006). In addition,
reactive glial proliferation may be epileptogenic.
PREOPERATIVE EVALUATION
A detailed preoperative epileptological and radiological work-up
tailored to the individual’s pathology allows the clinician to clas-
sify seizures according to the ILAE guidelines. Clinical history,
neurological examination, epilepsy-oriented MRI, scalp EEG, and
video-EEGare essential (VonDerBrelie and Schramm,2011). Spin
echo and gradient echo sequences using T1 and T2-weighed MRI
provide useful information on the CM hemodynamics; and also
permit to classify them in four types according to the ﬁndings
focused on signal characteristics (Zabramski et al., 1994).
Complementary studies include interictal and/or ictal SPECT,
PET, functional MRI, magnetoencephalography (Stefan et al.,
2004), intracarotid amobarbital testing (Stefan et al., 2004; Yeon
et al., 2009), electrocorticography (ECoG), or implantation of
intracerebral or subdural grid electrodeswhenneeded (Siegel et al.,
2000; Ferrier et al., 2007). Computer tomography with contrast
enhancement (Stavrou et al., 2008) or angiography can also be
used, although the latter usually fails to identify CMs (Gomori
et al., 1986; Stavrou et al., 2008).
MANAGEMENT
Radiosurgery leads to the progressive obliteration of CMs by
endothelial cell proliferation, with consequent luminal closure.
This process takes 1–3 years on average to complete (Schneider
et al., 1997), a period of time during which the risk of hemorrhage
remains. Moreover, serious complications are not uncommon,
with asmuch as 41%of patients presenting neurological deteriora-
tion after treatment and 27% requiring microsurgical extirpation
(Karlsson et al., 1998). In fact, pathological studies on previously
radiated patients undergoing surgery show that radiation does
not always warrant complete vascular obliteration (Gewirtz et al.,
1998).
Although seizure freedom is reported to reach 52% (Regis et al.,
2000), there is still a lack of consensus on the indications for radio-
surgery and the appropriate dose of irradiation, let alone the lim-
ited evidence supporting a protective role against rebleeding (Kim
et al., 1997; Pollock, 2008). For these reasons, excision remains
the optimal therapeutic strategy for patients with drug-resistant
epilepsy. Standardmicrosurgical technique is widely accepted, and
variations in surgical behavior exist among different groups. For
instance, some of them describe the routine (Ferroli et al., 2006)
or occasional (Kivelev et al., 2011) use of a stereotactic device
or frameless neuronavigation system. A mini-invasive transulcal
approach has been described (Ferroli et al., 2006); alternatively, a
transsylvian approach may be useful for anteromedial temporal
CMs, or transcortical excision, at times using intersulcal dissec-
tion, for other locations (Kivelev et al., 2011). Neurophysiologic
monitoring, in the formof direct corticalmapping andmonitoring
of neurological functions are used for CMs in eloquent locations
(Ferroli et al., 2006).
The amount of resected tissue is also a matter of discussion.
For instance, Yeon et al. (2009) take into account seizure fre-
quency, opting for more aggressive approaches for drug-resistant
epilepsy, i.e., extended rather than simple lesionectomy in patients
without mesial temporal lesions; and tailored resection rather
than standard temporal lobectomy for mesiotemporal CMs (Yeon
et al., 2009). On the other hand, Ferroli et al. (2006) endorse a
two-step surgical policy for patients with epilepsy secondary to
CMs, attempting at ﬁrst a pure lesionectomy, followed by inva-
sive localization and tailored removal of the epileptogenic zone in
those patients with drug-resistant seizures at 1–2 years follow-up
(Ferroli et al., 2006).
GENERAL OUTCOME
Up to 17% of patients may develop neurological symptoms (sen-
sorimotor deﬁcits and homonymous hemi or quadrantanopsia)
immediately after the operation (Ferroli et al., 2006; Stavrou et al.,
2008). Nonetheless, at follow-up, the rate of neurological deﬁcits
including severe headache, slight dysphasia, sensory disturbances,
ataxia, severe hemiparesis, pontocerebellar degeneration, descends
to 2.6–8% (Zevgaridis et al., 1996; Baumann et al., 2006; Ferroli
et al., 2006; Stavrou et al., 2008; Kivelev et al., 2011). No mortality
related to the procedure is reported.
Data is still limited regarding neuropsychological outcome. In
one study, 15% of patients complained of postoperative memory
deﬁcits, the half of these presented with only temporary short-
term memory decline. The rest underwent neuropsychological
evaluation, reporting new memory deﬁcit (4%) or worsening of
previous symptoms (4%). Postoperative depression and fatigue
were also assessed, ﬁnding a 9.4% rate of new-onset symptoms
(Kivelev et al., 2011).
SEIZURE OUTCOME
It is not easy to systematically evaluate seizure outcome due to
the following limitations: several studies include patients whose
main complaint was not epilepsy; deﬁnitions for intractability are
not always clear; group subdivision is not uniform among stud-
ies regarding the evolution, frequency, and/or severity of seizures;
control groups are compared against lesionectomy or epilepsy
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surgery, but rarely both. Finally, standardized classiﬁcations –
Engel et al. (1993), ILAE (Wieser et al., 2001) – are yet to be
universally adopted.
OVERALL SEIZURE OUTCOME
The largest series to date, including 168 patients, showed an Engel
I rate of 70% (48% IA) after 1 year. This ﬁgure declined to 68 and
65% for the second and third, respectively (Baumann et al., 2007),
a phenomenon previously described by Kim et al. (1997), arguably
due to the lack of follow-up for patients who became seizure-free.
In contrast, smaller series report up to 82–84% seizure freedom
rates (Casazza et al., 1996; Cappabianca et al., 1997).
LENGTH OF FOLLOW-UP
As commented above, slight differences on outcome are to be
expected as follow-up lengthens, namely after the third year (Bau-
mann et al., 2007; Von Der Brelie and Schramm, 2011), while this
is not a constant ﬁnding (Yeon et al., 2009).
LOBAR LOCATION
There seems not to be any correlation between the lobar loca-
tion nor the side of CMs and seizure freedom (Cappabianca et al.,
1997; Baumann et al., 2007). At 1-year follow-up, the outcome
was better for patients with mesiotemporal cavernomas and worst
for neocortical locations (Baumann et al., 2007), but subsequent
comparisons showed no differences.
Lesion location within the temporal lobe does not correlate
with epilepsy outcome, i.e., patients with mesial or lateral lesions
have the same chance of having a favorable seizure outcome (Yeon
et al., 2009; Kivelev et al., 2011).
SIZE OF LESION
A size of less than 1.5 cm diameter has been associated with better
seizure control during the ﬁrst 2 years but no differences arise at
longer evaluation (Baumann et al., 2007; Englot et al., 2011), a
ﬁnding conﬁrmed later on (Yeon et al., 2009; Englot et al., 2011).
TYPE OF SEIZURES
Patients with simple partial and complex partial seizures are more
likely to become asymptomatic than patients affected by secon-
darily generalized seizures, although this analysis is not routinely
performed by most of studies (Baumann et al., 2007; Englot et al.,
2011).
DURATION OF EPILEPSY
The theory of secondary epileptogenesis states that a prolonged
preoperative history of epilepsy brings an increased risk for worse
seizure outcome as a result of developing remote epileptogenic
foci (Morrell, 1985; Cohen et al., 1995; Cappabianca et al., 1997).
The impact of this variable is controversial, for there are series that
correlate the duration of epilepsy with seizure outcome, i.e., they
report a slightly (Stavrou et al., 2008) or signiﬁcantly (Cohen et al.,
1995; Casazza et al., 1996; Zevgaridis et al., 1996; Cappabianca
et al., 1997; Schroeder et al., 1997; Moran et al., 1999; Hammen
et al., 2007; Englot et al., 2011) poorer outcome for patients with
more than 1–2 years of seizure history, with the notable exception
of patients with sporadic seizures over a long period of time. On
the other hand, others report similar results for patients with 0.5
to more than 10 years of seizure history (Baumann et al., 2007;
Kivelev et al., 2011).
Yeon et al. (2009) did a sub-analysis within their non-
lesionectomy group, for which duration of illness showed sta-
tistical signiﬁcance only when Engel class IA was set aside and
compared to the other classes considered as a whole (Yeon et al.,
2009).
GENDER
Gender differences on outcome, when present, show that men
seem to have a higher chance to become seizure-free (Cohen et al.,
1995; Cappabianca et al., 1997; Stavrou et al., 2008), but, once
again, it is not a constant ﬁnding (Baumann et al., 2007; Yeon
et al., 2009).
AGE
Some studies show a better outcome in patients whose ﬁrst seizure
occurred after age 30 (Cohen et al., 1995; Baumann et al., 2007) or
40 (Cappabianca et al., 1997). In contrast, others considered age at
onset to be irrelevant (Moran et al., 1999; Stavrou et al., 2008;Yeon
et al., 2009). Baumann et al. (2007) found better seizure control
for patients aged 30 or more at the time of surgery.
PREOPERATIVE EEG
There is a reported correlation between epileptiform abnormali-
ties after the ﬁrst unprovoked seizure and seizure recurrence (Van
Donselaar et al., 1992). Subjectswithnormal ﬁndings onpreopera-
tive scalp EEG have better odds of being seizure free (Kivelev et al.,
2011), as opposed to patients with multifocal epileptic activity
(Baumann et al., 2007).
POSTOPERATIVE EEG
Kivelev et al. (2011) found no correlation between neurophys-
iological evaluation and epilepsy control, but an earlier study
described an association of interictal epileptiform activity and
seizure persistence (Di Gennaro et al., 2004).
LESION BLEEDING AT THE TIME OF SURGERY
Perilesional bleeding – old or recent – whether documented on
MRI or directly observed during surgery, did not affect outcome
on Baumann et al. (2007) study, but was considered as negative
prognostic factor by Stefan et al. (2004) and Stefan and Hammen
(2004).
FREQUENCY AND NUMBER OF SEIZURES
In two studies patients were classiﬁed according to the total num-
ber of seizures in three groups, i.e., 1, 2–5, and>5 seizures, achiev-
ing a seizure-free rate of 100, 69–100, and 62.5–69%, respectively
(Cappabianca et al., 1997; Kivelev et al., 2011).
A high seizure frequency before surgery has been shown to
worsen the postoperative outcome in some series (Cohen et al.,
1995; Cappabianca et al., 1997; Moran et al., 1999; Stefan and
Hammen, 2004; Ferroli et al., 2006; Englot et al., 2011) but had no
effect in others (Casazza et al., 1996; Baumann et al., 2007; Stavrou
et al., 2008). In their study, Yeon et al. (2009) named “intractable”
those patients presenting>1monthly seizure over a 1-year period.
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Seventy-two percent of these patients were in Engel I class (54.5%
IA), as opposed to 89.5% (84.2% IA) of subjects with sporadic
seizures (Yeon et al., 2009).
THE ROLE OF “PURE” LESIONECTOMY
The extension of excision is subject of controversy. Several studies
report a better outcome when surrounding gliosis and hemo-
siderin are removed (Piepgras et al., 1993; Yeh et al., 1993; Cohen
et al., 1995; Casazza et al., 1997; Kim et al., 1997; Siegel et al., 2000;
Stefan and Hammen, 2004; Baumann et al., 2006; Hammen et al.,
2007; Stavrou et al., 2008; Menzler et al., 2010), while others fail to
ﬁnd signiﬁcant differences (Casazza et al., 1996; Zevgaridis et al.,
1996; Cappabianca et al., 1997).
The problem arises when trying to compare techniques due to
the lack of a control group – one of medical treatment – that can
be compared with both lesionectomy and more extended resec-
tions in the same study. For instance, Yeon et al. (2009) found
no difference between lesionectomy and other methods; but the
decision of what procedure to perform was predetermined by
their protocol, which, in turn favors the use of a more aggres-
sive approach for patients with intractable epilepsy, a group in
which blood degradation products are thought to play a major
role in the aforementioned mechanisms of seizure propagation
and secondary epileptogenesis (Morrell, 1991; Yeh and Privitera,
1991).
Lesionectomy alone appears to be beneﬁcial for patients with
sporadic seizures or evolution shorter than 1 year (Acciarri et al.,
1995; Cohen et al., 1995; Casazza et al., 1996; Zevgaridis et al.,
1996; Cappabianca et al., 1997; Ferroli et al., 2006). In this subset
of individuals, it has been suggested to reserve a more invasive
approach for persisting or relapsing cases (Yeon et al., 2009).
Growing evidence both in clinical and basic grounds suggests
that resection of all cortical hemosiderin might improve seizure
outcome, whereas incomplete removal of subcortical hemosiderin
to spare eloquent tracts might not inﬂuence postoperative seizures
(Siegel et al., 2000; Baumann et al., 2006; Menzler et al., 2010).
In particular, transoperative ECoG-guided resection is associated
with more extensive resections and, more importantly, is a good
prognostic factor for seizure freedom when compared to patients
without ECoG (Sugano et al., 2007; Komotar et al., 2008; Van
Gompel et al., 2009).
CONCLUSION
Comprehensive research is still needed to reach fully understand-
ing of CMs on the molecular level and its implications on clinical
grounds (Raychaudhuri et al., 2005).
Earlymicrosurgical resection is an effective and safe therapy for
patients with CMs and symptomatic epilepsy, let alone CMs’ well
known inherent risk of bleeding. For this purpose, the seizures
must be carefully classiﬁed; the site of the lesion and the pres-
ence/absence of dual pathology accurately determined; and the
focal epileptic activity, the risk of bleeding,andneuropsychological
status carefully evaluated (Stefan and Hammen, 2004).
It is strongly recommended the complete lesion removal includ-
ing the neighboring epileptogenic brain tissue for drug-resistant
epilepsy, performing transoperative neurophysiological monitor-
ing (ECoG), because subtotal removal of a CM is associated with a
high risk of symptomatic recurrences (Kim et al., 1997; Baumann
et al., 2006; Hammen et al., 2007; Englot et al., 2011).
Published case series and reviews emphasize the need of fur-
ther prospective studies with homogeneous inclusion criteria with
the purpose of generating comparable data (Von Der Brelie and
Schramm, 2011). In this spirit, we suggest that upcoming stud-
ies adhere to the revised deﬁnition of drug-resistance (Kwan et al.,
2010), state clearly the demographics of the group studied, the type
and number of seizures, illness duration, history of bleeding, neu-
rological examination, paraclinical ﬁndings – MRI, EEG, video-
EEG, and,when suitable,metabolic and/or functional studies, size,
location, surgical approach, resection type, transoperatory clinical
and paraclinical ﬁndings, transient and permanent neurological
deﬁcits, the use of Engel and/or ILAE outcome classiﬁcations, and
the length of follow-up.
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